Antibody Immunity Induced by H7N9 Avian Influenza Vaccines: Evaluation Criteria, Affecting Factors, and Implications for Rational Vaccine Design.

about

Development of in vitro and in vivo neutralization assays based on the pseudotyped H7N9 virus.Temperature Sensitive Mutations in Influenza A Viral Ribonucleoprotein Complex Responsible for the Attenuation of the Live Attenuated Influenza Vaccine

P2860

Q55308512-1F1D8426-F32E-41B1-B2E7-30BF313561AA Q57466491-EA48FF9A-7A43-419A-9F33-9BD3823F39C0

P2860

Antibody Immunity Induced by H7N9 Avian Influenza Vaccines: Evaluation Criteria, Affecting Factors, and Implications for Rational Vaccine Design.

Item

http://www.wikidata.org/entity/Q41919615

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Antibody Immunity Induced by H ...... s for Rational Vaccine Design.

@en

type

Item

label

Antibody Immunity Induced by H ...... s for Rational Vaccine Design.

@en

prefLabel

Antibody Immunity Induced by H ...... s for Rational Vaccine Design.

@en

P1476

Antibody Immunity Induced by H ...... s for Rational Vaccine Design.

@en

P2093

Xinan Jiao

http://www.w3.org/2001/XMLSchema#string

Xiufan Liu

http://www.w3.org/2001/XMLSchema#string

Zenglei Hu

http://www.w3.org/2001/XMLSchema#string

P2860

AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland

Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities

Human infection with a novel avian-origin influenza A (H7N9) virus

Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults

H7N9 Live Attenuated Influenza Vaccine Is Highly Immunogenic, Prevents Virus Replication, and Protects Against Severe Bronchopneumonia in Ferrets.

Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.

Cross-protective efficacy of baculovirus displayed hemagglutinin against highly pathogenic influenza H7 subtypes.

A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults.

A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine.

Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.

P304

1898

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FMICB.2017.01898

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29018438

http://www.w3.org/2001/XMLSchema#string

P932

5622983

http://www.w3.org/2001/XMLSchema#string

Antibody Immunity Induced by H7N9 Avian Influenza Vaccines: Evaluation Criteria, Affecting Factors, and Implications for Rational Vaccine Design.

about

P2860

P2860

Antibody Immunity Induced by H7N9 Avian Influenza Vaccines: Evaluation Criteria, Affecting Factors, and Implications for Rational Vaccine Design.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P932